Purpose Recent reports have described a spectrum of uncommon findings of intraocular
inflammation (IOI), retinal vasculitis and/or retinal vascular occlusion in patients with …

Intravitreally injected anti‐vascular endothelial growth factor (anti‐VEGF) agents are first‐
line treatment for neovascular age‐related macular degeneration (nAMD). Phase 3 trials …

Background Brolucizumab has recently been approved in Europe as a novel treatment for
patients with neovascular age-related macular degeneration (nAMD). We report on early …

Importance Outcome data are limited regarding early experience with brolucizumab, the
most recently approved anti–vascular endothelial growth factor (VEGF) agent for the …

Purpose This analysis of the pivotal phase III HAWK and HARRIER trials aimed to provide
insights on the timing of presentation, management, and outcomes of intraocular …

The aim of the present study was to determine the efficacy and safety of intravitreal
brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real …

Purpose: The aim of this study was to evaluate the effect of switching treatment in eyes with
neovascular age-related macular degeneration (nAMD) and treatment intervals of≤ 6 …

Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab
injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under …

Purpose: To assess the morphological and functional outcomes within the first year of
treatment with intravitreal brolucizumab for refractory neovascular age-related macular …

To report the early efficacy and safety outcomes of treatment with intravitreal injections of
brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration …